Pharmaceutical Company Vivus Receives FDA Approval For Spray To Treat Menopausal Symptoms
St. Louis-based KV Pharmaceutical, which bought the marketing rights for EvaMist earlier this year, will pay $140 million to Vivus under an agreement reached between the two companies, Reuters reports. KV intends to launch the product during the second half of fiscal year 2008 (Relia/Tickoo, Reuters, 7/30).
According to the Mercury News, Vivus executives said EvaMist can be used to treat hot flashes with lower doses of estrogen than other products on the market (San Jose Mercury News, 7/31). Marc Hermelin, KV board chair and CEO, said, "We believe our existing presence in the women's health market and our specialized focus on the ob-gyn community through our dedicated sales force will allow us to successfully promote the benefits of EvaMist to physicians and patients" (KV Pharmaceutical release, 7/30).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
View drug information on Evamist.
Companiei farmaceutice Vivus primeºte aprobarea FDA pentru spray pentru a trata simptomele menopauzal - Pharmaceutical Company Vivus Receives FDA Approval For Spray To Treat Menopausal Symptoms - articole medicale engleza - startsanatate